Lumakras, an oral tablet from Amgen Inc. made for the treatment of metastatic non-small cell lung cancer, was given accelerated approval from the U.S. Food and Drug Administration.   

Lumakras has a U.S. list price of $17,900 per month.  

“The FDA approval of Lumakras is a breakthrough moment for patients with KRAS G12C-mutated non-small cell lung cancer because there is now a targeted therapy for this common, but previously elusive, mutation,” Dr. David Reese, Amgen’s executive vice president of research and development, said in a statement.  


Join our Membership to get the full story.

Are you a current Member? Sign In